文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Ponatinib对比伊马替尼一线治疗费城染色体阳性急性淋巴细胞白血病:一项随机临床试验

Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01

这项全球注册性3期开放标签试验纳入245例新诊断费城染色体阳性急性淋巴细胞白血病成人患者,按2:1随机接受Ponatinib 30 mg/d或伊马替尼600 mg/d联合减低强度化疗。Ponatinib组第3周期末MRD阴性完全缓解率显著高于伊马替尼组(34.4% vs 16.7%),安全性特征相当。

要点

  • Ponatinib组MRD阴性完全缓解率为34.4%,伊马替尼组为16.7%,差异有统计学意义。
  • Ponatinib组中位无事件生存期未达到,伊马替尼组为29个月。
  • 两组最常见不良事件相似,动脉闭塞事件发生率低且相当。

核心结论

  • 在新诊断费城染色体阳性急性淋巴细胞白血病成人中,Ponatinib联合减低强度化疗在第3周期末的MRD阴性完全缓解率优于伊马替尼,安全性特征与伊马替尼相当。

研究设计与样本

  • 全球注册性3期开放标签随机对照试验,2019年1月至2022年5月在77个中心纳入245例18岁及以上新诊断费城染色体阳性急性淋巴细胞白血病成人患者,按2:1随机分配。
  • Ponatinib组30 mg/d,伊马替尼组600 mg/d,均联合减低强度化疗,第20周期后改为单药;Ponatinib组达到MRD阴性完全缓解后减至15 mg。
  • 本分析末次随访日期为2022年8月12日。

主要发现

  • 主要终点MRD阴性完全缓解率(第3周期末维持至少4周)Ponatinib组为34.4%(53/154),伊马替尼组为16.7%(13/78),风险差0.18(95%CI 0.06-0.29),P=0.002。
  • 截至数据截止日,无事件生存期未达到预设事件数;Ponatinib组中位无事件生存期未达到,伊马替尼组为29个月。
  • 动脉闭塞事件发生率Ponatinib组为2.5%,伊马替尼组为1.2%,两组均不常见且相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), disease progression due to acquired resistance to first- or second-generation BCR::ABL1 tyrosine kinase inhibitors is common. Ponatinib inhibits BCR::ABL1 and all single-mutation variants, including T315I. OBJECTIVE: To compare frontline ponatinib vs imatinib in adults with newly diagnosed Ph+ ALL. DESIGN, SETTING, AND PARTICIPANTS: Global registrational, phase 3, open-label trial in adults aged 18 years or older with newly diagnosed Ph+ ALL. From January 2019 to May 2022, eligible patients at 77 sites were randomized 2:1 to ponatinib (30 mg/d) or imatinib (600 mg/d) with reduced-intensity chemotherapy, followed by single-agent ponatinib or imatinib after the cycle 20 phase of the trial. The last date of follow-up for this analysis was August 12, 2022. INTERVENTION: Patients received ponatinib, 30 mg/d, or imatinib, 600 mg/d, with reduced-intensity chemotherapy, followed by single-agent ponatinib or imatinib after cycle 20. The ponatinib dose was reduced to 15 mg on achievement of minimal residual disease-(MRD) negative complete remission. MAIN OUTCOMES AND MEASURES: The primary end point of this interim analysis was MRD-negative complete remission (≤0.01% BCR::ABL1 [MR4] centrally assessed by reverse transcriptase-quantitative polymerase chain reaction), with complete remission maintained for at least 4 weeks at the end of cycle 3. The key secondary end point was event-free survival. RESULTS: Of 245 patients randomized (median age, 54 years; 133 [54.3%] female), 232 (ponatinib, n = 154; imatinib, n = 78) who had p190 or p210 dominant isoforms verified by the central laboratory were analyzed for the primary end point. The MRD-negative complete remission rate (primary end point) was significantly higher with ponatinib (34.4% [53/154]) vs imatinib (16.7% [13/78]) (risk difference, 0.18 [95% CI, 0.06-0.29]; P = .002). At the data cutoff, event-free survival had not met the prespecified number of events. Median event-free survival was not reached in the ponatinib group and was 29 months in the imatinib group. The most common adverse events were similar between treatment groups. Arterial occlusive events were infrequent and comparable between groups (ponatinib, 2.5%; imatinib, 1.2%). CONCLUSIONS AND RELEVANCE: Ponatinib demonstrated a superior rate of MRD-negative complete remission at the end of induction vs imatinib when combined with reduced-intensity chemotherapy in adults with newly diagnosed Ph+ ALL. The safety profile of ponatinib was comparable with imatinib. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03589326.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Jabbour E, Kantarjian HM, Aldoss I, et al. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2024. PMID: 38722621. doi:10.1001/jama.2024.4783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。